全球骨质减少治疗市场 – 行业趋势和 2031 年预测

骨质减少治疗市场分析和规模

全球骨质疏松治疗市场的发展主要得益于人们对骨密度异常的认识和诊断不断提高，尤其是在全球老龄化人口中。由于骨质疏松是骨质疏松症的前兆，因此注重早期干预和预防的医疗保健计划正日益受到重视。诊断技术的进步进一步推动了市场的增长，这些技术能够实现骨骼健康的早期检测和监测。治疗策略包括一系列药物选择，包括双膦酸盐、激素疗法和其他旨在提高骨密度的药物。此外，饮食补充剂、运动方案和钙/维生素 D 补充剂等生活方式的改变在控制骨质疏松方面发挥着关键作用。         

2023 年全球骨质减少治疗市场规模价值 147.7 亿美元，预计到 2031 年将达到 206.8 亿美元，2024 年至 2031 年预测期内的复合年增长率为 4.3%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分       

Market Definition

Osteopenia treatment refers to medical interventions aimed at managing and potentially reversing lower-than-normal bone density, which characterizes osteopenia. This condition is considered a precursor to osteoporosis, where bones become weak and brittle. Treatment typically involves lifestyle modifications such as exercise and dietary changes, along with medications like bisphosphonates or hormone therapy in more severe cases.       

Osteopenia Treatment Market Dynamics

Drivers

• Advancements in Diagnostic Technologies

Technological advancements in bone density scanning and diagnostic tools have revolutionized the early detection and monitoring of osteopenia, thereby driving significant growth in the market. These advancements, including dual-energy X-ray absorptiometry (DEXA) and quantitative ultrasound (QUS), enable healthcare providers to accurately assess bone density levels, diagnose osteopenia at earlier stages, and monitor changes over time. This enhanced diagnostic capability not only improves patient outcomes by enabling timely intervention but also expands the market by increasing the overall demand for osteopenia treatments. 

• Impact of the Aging Population

Aging is associated with physiological changes in bone structure and density, leading to a higher susceptibility to osteopenia and its progression to osteoporosis. With older individuals experiencing a decline in bone mass and strength, there is an amplified need for effective treatments to mitigate the risks of fractures and other complications associated with bone frailty. For instance, in February 2023, the World Health Organization (WHO) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases (ESCEO) agreed to create a strategic plan addressing bone health and aging. They aim to promote a public health strategy aimed at preventing fractures in elderly individuals. This demographic shift not only underscores the growing demand for osteopenia treatments but also emphasizes the importance of healthcare strategies focused on maintaining bone health and quality of life in elderly populations worldwide.

• Focus on Combination Therapies

The development of combination therapies that address multiple aspects of bone health, such as bone formation and resorption, while minimizing side effects presents a promising opportunity in the osteopenia treatment market. These therapies may include a combination of medications, dietary supplements, and lifestyle modifications tailored to individual patient needs. By targeting different mechanisms of bone metabolism simultaneously with alternative treatment for osteopenia, combination therapies aim to improve treatment efficacy and patient outcomes, thereby expanding market potential and meeting the diverse needs of patients with osteopenia.

Opportunities

• Lifestyle Modifications and Preventive Care

There is a growing emphasis on preventive healthcare measures, including lifestyle modifications such as regular exercise, a balanced diet, and adequate intake of calcium and vitamin D, which play a crucial role in supporting bone health and preventing osteopenia. These lifestyle interventions not only promote overall well-being but also reduce the risk of bone density disorders like osteopenia. As public awareness about the importance of these preventive measures increases, so does the demand for osteopenia treatments, driving market growth and creating opportunities for healthcare providers to offer comprehensive bone health management strategies.            

• Patient Education and Engagement

Enhanced patient education programs and initiatives aimed at improving treatment adherence and outcomes are critical for driving market growth in osteopenia treatment. Educating patients about the importance of medication adherence, lifestyle modifications, and regular follow-up visits empowers them to actively participate in their care, leading to better treatment compliance and overall satisfaction. By fostering patient engagement through personalized education and support, healthcare providers can enhance patient outcomes, reduce healthcare costs associated with non-adherence, and capitalize on opportunities for market expansion.

Restraints/Challenges

• High Treatment Costs 

The cost of osteopenia treatments, encompassing medications, diagnostic procedures like bone density scans, and ongoing management, can pose a significant barrier to market growth. High treatment costs may deter patients from seeking timely diagnosis and treatment, particularly in regions with limited healthcare resources or inadequate insurance coverage for bone health-related expenses.  

• Potential Side Effects of Medications

Concerns over potential side effects associated with osteopenia treatment medications, such as bisphosphonates, including gastrointestinal disturbances and osteonecrosis of the jaw, may influence patient adherence and treatment uptake. These side effects can lead to patient hesitancy or discontinuation of therapy, impacting treatment outcomes and overall market growth.

本市场报告详细介绍了最新发展、贸易法规、进出口分析、生产分析、价值链优化、市场份额、国内和本地市场参与者的影响，分析了新兴收入领域的机会、市场法规的变化、战略市场增长分析、市场规模、类别市场增长、应用领域和主导地位、产品批准、产品发布、地域扩展、市场技术创新。如需获取更多市场信息，请联系 Data Bridge Market Research 获取分析师简报，我们的团队将帮助您做出明智的市场决策，实现市场增长。

最新动态

• 2024 年 3 月，Bone Health Technologies (BHT) 获得了一轮 500 万美元的融资，旨在促进低骨密度人群的护理。此轮融资吸引了 Esplanade Ventures、Berkeley Catalyst Fund 和全球医疗技术领域的知名企业 Terumo Medical 的投资。随着 BHT 即将获得其 Osteoboost 振动可穿戴设备的 FDA 批准的最后阶段，此次资金注入正值关键时刻
• 2024 年 1 月，骨骼健康解决方案领域的领导者 Bone Health Technologies 在获得 FDA 批准后推出了 Osteoboost。这款创新设备是首个针对绝经后骨质疏松症女性的非药物处方治疗产品。这款可穿戴腰带可对腰椎和臀部施加精确、校准的振动，旨在缓解骨骼强度和密度的下降。Osteoboost 的获批为低骨密度患者带来了一种突破性的治疗选择，是女性健康进步的一个里程碑

骨质疏松治疗市场范围

市场根据类型、给药途径和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

• 双膦酸盐
• 降钙素
• 激素治疗
• 甲状旁腺激素相关治疗 (PTHrP) 类似物
• 选择性雌激素受体调节剂
• 其他的

给药途径

• 口服
• 注射剂
• 其他的

分销渠道

• 医院 药店
• 零售药店
• 其他的

骨质减少治疗市场区域分析/见解

对市场进行分析，并按上述国家、类型、给药途径和分销渠道提供市场规模洞察和趋势。

市场覆盖的国家包括美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷以及南美洲其他地区。

由于知名的关键参与者的存在，北美有望主导市场，这些参与者为激烈的竞争格局做出了贡献。该地区受益于多种治疗选择，可满足不同患者的需求，并得到以先进的医疗基础设施和专业护理设施而闻名的成熟医疗保健行业的支持。            

由于研发力度加大、医疗基础设施投资增加、治疗方案需求不断增长以及人口老龄化，预计亚太地区在预测期内将出现显著增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

该市场还为您提供每个国家/地区资本设备医疗支出增长、市场上不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对市场的影响的详细市场分析。数据适用于 2016-2021 年的历史时期。

竞争格局和骨质减少治疗市场份额分析

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

市场上的一些主要参与者包括：

• 艾尔建公司（爱尔兰）
• 安进公司（美国）
• Actavis Plc.（爱尔兰）
• 礼来公司 (美国)
• F. Hoffmann La Roche Ltd.（瑞士）
• 葛兰素史克制药有限公司（英国）
• 默克公司（瑞士）
• 诺华公司（瑞士）
• 诺和诺德公司（丹麦）
• 辉瑞公司（美国）
• Teva Pharmaceuticals Industries Ltd.（以色列）

SKU-63918